Bile Acid Synthetic Defects (BASDs): Comprehensive Overview

I. Introduction

Bile acid synthetic defects are rare, autosomal recessive inborn errors of metabolism that impair the biosynthesis of primary bile acids—cholic acid and chenodeoxycholic acid—from cholesterol. These defects disrupt hepatic bile flow and intestinal fat absorption, and can lead to progressive liver disease, fat-soluble vitamin deficiencies, and systemic complications. At least nine distinct enzymatic defects have been identified.

• Estimated incidence: 1–9 per 1,000,000 live births
• Inheritance: Autosomal recessive
• Diagnosis: Often missed without targeted biochemical testing

II. Bile Acid Physiology and Pathogenesis

A. Normal Bile Acid Synthesis

• Begins with cholesterol in hepatocytes
• Involves 14 enzymatic steps across two major pathways:
  • Neutral (classic) pathway: initiated by CYP7A1
  • Acidic pathway: initiated by CYP27A1
• Produces:
  • Cholic acid (CA)
  • Chenodeoxycholic acid (CDCA)
• Conjugated with glycine or taurine to increase solubility

B. Functions of Bile Acids

• Promote bile flow and cholesterol excretion
• Facilitate absorption of fats and fat-soluble vitamins
• Detoxify bilirubin and xenobiotics
• Act as signaling molecules in glucose and lipid metabolism

C. Pathophysiology of BASDs

• Defective enzymes block synthesis of primary bile acids
• Leads to:
  • Accumulation of hepatotoxic intermediates
  • Impaired bile flow (cholestasis)
  • Malabsorption and vitamin deficiencies
  • Progressive liver injury and fibrosis

III. Clinical Presentation

BASDs typically present in infancy or early childhood with signs of cholestatic liver disease, but may also manifest later depending on severity.

• Conjugated hyperbilirubinemia
• Normal or low serum bile acids
• Normal or minimally elevated GGT
• Absence of pruritus
• Hepatomegaly ± splenomegaly
• Steatorrhea and fat-soluble vitamin deficiency
• Rickets or coagulopathy

IV. Diagnostic Evaluation

A. Initial Workup

• Liver function tests (AST, ALT, bilirubin, GGT)
• Serum bile acid levels
• Coagulation profile (PT/INR)
• Fat-soluble vitamin levels

B. Specialized Testing

• Urine bile acid analysis via:
  • Fast atom bombardment mass spectrometry (FAB-MS)
  • Gas chromatography-mass spectrometry (GC-MS)
• Liver biopsy: giant cell transformation, portal inflammation, fibrosis
• Genetic testing: confirms specific enzyme defects

V. General Treatment Principles

• Oral bile acid therapy (e.g., cholic acid [Cholbam®])
• Nutritional support: MCT formulas, vitamins A, D, E, K
• Liver transplantation in advanced cases
• Monitoring: liver function, growth, bile acid profiles

VI. Specific Bile Acid Synthetic Defects

1. 3β-Hydroxy-Δ5-C27 Steroid Oxidoreductase Deficiency (3βHSD)

• Most common BASD
• Presents with neonatal cholestasis, hepatomegaly, steatorrhea
• Labs: Normal GGT, low/normal total bile acids, elevated transaminases
• Urine: Increased di- and trihydroxycholenoic (bile) acids
• Liver biopsy: Giant cell hepatitis, portal inflammation, perilobular fibrosis
• Mutation analysis of the HSD3B7 gene
  
• Treatment: Cholic acid

2. Oxysterol 7α-Hydroxylase Deficiency

• Rare (<5 cases)
• Severe neonatal liver failure, hepatosplenomegaly
• Urine: Absent primary bile acids
• FAB-MS: Increased sulfate and glycosulfate conjugates of 3β-monohydroxy bile acids
• Liver biopsy: Lobular disarray, giant cells, portal inflammation
• Mutation analysis of the CYP7B1 gene
  

3. Δ4-3-Oxosteroid 5β-Reductase Deficiency

• Neonatal cholestasis, coagulopathy, normal GGT
• FAB-MS: Increased 3-oxo-7α bile acids; absence of normal 5β bile acids
• Urine/serum GC-MS: Accumulated Δ4-3-oxo-7α intermediates
• Liver biopsy: Neonatal hepatitis pattern
• Mutation analysis of the AKR1D1 gene
• Treatment: Cholic acid

4. Cerebrotendinous Xanthomatosis (CTX)

• Neonatal cholestasis resolves by 6 months
• Adult features: Neurologic dysfunction, cataracts, tendon xanthomas
• Serum cholestanol: Elevated (key marker)
• Urine bile acids: May show abnormal intermediates in infancy
• FAB-MS: Reduced chenodeoxycholic acid; increased bile alcohols
  
• Liver biopsy: May show neonatal cholestasis early; not typical in adults
• Mutation analysis of CYP27A1 gene
  
• Treatment: Chenodeoxycholic acid or cholic acid + statins

5. Alpha-Methylacyl-CoA Racemase Deficiency

• Cholestasis, vitamin deficiency, coagulopathy
• Urine: Increased trihydroxycholestanoic and pristanic acids
• FAB-MS: Absence of normal bile acids; presence of racemase substrates
• Liver biopsy: Giant cell hepatitis
• Electron Microscopy: decreased peroxisomes
• Treatment: Cholic acid; liver transplant if severe
• Mutation analysis of the AMACR gene

6. Bile Acid Conjugation (Amidation) Defects

• Final step in bile acid synthesis
• Symptoms: Malabsorption, vitamin deficiency, liver failure
• Urine: Complete absence of glycine- and taurine-conjugated bile acids
• FAB-MS: Confirms lack of conjugated bile acids
• Liver Biopsy: May show cholestasis and hepatocellular injury
• Mutation analysis of:
  
• SLC27A5 (bile acid-CoA ligase)
• BAAT (bile acid-CoA:amino acid N-acyltransferase)
• Treatment: Oral conjugated bile acids + vitamins

TABLE

VII. References

• Heubi JE, Setchell KD, Bove KE. Inherited disorders of bile acid metabolism. J Pediatr Gastroenterol Nutr. 2007;45(6):661–670.
• EASL Clinical Practice Guidelines: Liver diseases in children. J Hepatol. 2022.
• NASPGHAN Guidelines: Evaluation of cholestatic jaundice in infants. JPGN. 2017.
• Cholbam® (cholic acid) Prescribing Information. Retrophin Inc.
• Clayton PT. Bile acid synthesis defects. Ann Clin Biochem. 2011;48(Pt 4):332–340.